Valeant News
Most Popular Valeant Story
Valeant counts itself out of ISTA's strategic options
Valeant Pharmaceuticals CEO Michael Pearson has walked away from another deal. The Canadian drugmaker withdrew its $7.50-per-share bid to acquire ISTA Pharmaceuticals, one day ahead of its official Read more...
Latest Headlines
- January 30, 2012
- January 9, 2012
- January 4, 2012
- December 19, 2011
- December 16, 2011
- August 31, 2011
- August 9, 2011
- July 26, 2011
- July 18, 2011
- July 11, 2011
- June 13, 2011
- May 31, 2011
- May 24, 2011
- May 3, 2011
- April 21, 2011
- April 7, 2011
- April 6, 2011
- April 1, 2011
- March 31, 2011
- March 30, 2011
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
